Want to see FR:ALMKT full AI Analyst Report?
Top Page
MAUNA KEA TECHNOLOGIES
(ALMKT)
Select Model
Select Model
Rating:48Neutral
Price Target:
€0.16
▼(-1.25% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance: persistent operating losses, ongoing negative free cash flow, and negative equity indicate elevated solvency and funding risk, even after debt reduction. Technical signals also remain soft with negative MACD and low RSI/Stochastic. Valuation provides some support via a low P/E, but it is not enough to offset the core operating and cash-flow weaknesses.
Positive Factors
Revenue Recovery
The sharp 2025 revenue recovery shows that demand for Mauna Kea’s endomicroscopy offering can return after a weak period, supporting installed-base expansion and future recurring probe revenue if adoption becomes more consistent.
Negative Factors
Deep Operating Losses
The very negative operating margin shows that the core business is not yet covering its operating cost base. Sustained losses could require restructuring, additional funding, or slower investment, limiting the benefits of revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The sharp 2025 revenue recovery shows that demand for Mauna Kea’s endomicroscopy offering can return after a weak period, supporting installed-base expansion and future recurring probe revenue if adoption becomes more consistent.
Read all positive factors
MAUNA KEA TECHNOLOGIES (ALMKT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€29.49M
Dividend YieldN/A
Average Volume (3M)534.64K
Price to Earnings (P/E)7.4
Beta (1Y)0.86
Revenue Growth7.43%
EPS GrowthN/A
CountryFR
Employees59
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding195,260,220
10 Day Avg. Volume399,583
30 Day Avg. Volume534,637
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.65
Price to Sales (P/S)1.55
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€7.75M
MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model
Company Description
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Ce...
How the Company Makes Money
Mauna Kea Technologies primarily generates revenue from selling and/or leasing its endomicroscopy platform (notably its CLE systems) to hospitals and endoscopy centers, and from recurring sales of single-use or limited-use consumables associated w...
MAUNA KEA TECHNOLOGIES Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.22M | 7.66M | 11.03M | 7.48M | 7.70M |
| Gross Profit | 6.20M | 6.44M | 8.93M | 3.91M | 5.71M |
| EBITDA | 12.87M | -7.97M | -1.46M | -9.93M | -11.23M |
| Net Income | 10.77M | -10.40M | -3.73M | -11.18M | -13.45M |
Balance Sheet | |||||
| Total Assets | 13.41M | 16.25M | 22.94M | 19.79M | 24.75M |
| Cash, Cash Equivalents and Short-Term Investments | 4.97M | 1.92M | 7.91M | 3.15M | 11.89M |
| Total Debt | 12.08M | 31.93M | 29.77M | 29.20M | 28.70M |
| Total Liabilities | 18.23M | 40.63M | 40.21M | 39.72M | 35.08M |
| Stockholders Equity | -4.82M | -24.39M | -17.28M | -19.92M | -10.33M |
Cash Flow | |||||
| Free Cash Flow | -3.95M | -6.54M | -1.14M | -8.97M | -11.37M |
| Operating Cash Flow | -3.74M | -6.32M | -753.00K | -8.83M | -10.27M |
| Investing Cash Flow | -200.00K | -149.00K | -354.00K | -57.00K | -1.14M |
| Financing Cash Flow | 6.95M | 483.00K | 5.96M | 109.00K | 14.65M |
MAUNA KEA TECHNOLOGIES Technical Analysis
Negative
0.16
Price Trends
0.16
Negative
0.16
Negative
0.15
Negative
Market Momentum
>-0.01
Positive
42.14
Neutral
7.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMKT, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.16, and above the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.14 is Neutral, neither overbought nor oversold. The STOCH value of 7.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMKT.
MAUNA KEA TECHNOLOGIES Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | €36.73M | -0.92 | -96.46% | ― | 0.87% | 46.31% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €204.11M | 42.98 | 2.71% | ― | 9.08% | 21.19% | |
48 Neutral | €29.49M | 7.39 | -58.93% | ― | 7.43% | ― | |
47 Neutral | €46.50M | -5.87 | 222.05% | ― | 42.86% | 13.93% | |
46 Neutral | €22.10M | -5.13 | -22.03% | ― | 37.28% | 7.83% | |
42 Neutral | €178.15M | -3.16 | 90.10% | ― | 1.79% | 15.89% |
* General Sector Average
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.15
0.07
85.19%
FR:ALTHE
Theraclion SA
0.64
-0.21
-24.35%
FR:ALNOV
Novacyt
0.49
0.03
6.03%
FR:ALERS
Eurobio-Scientific SA
20.20
-5.40
-21.09%
FR:ALIKO
Ikonisys SA
1.40
-0.12
-7.89%
FR:ALMDT
Median Technologies
3.63
0.68
23.05%
MAUNA KEA TECHNOLOGIES Corporate Events
Mauna Kea Technologies Updates Share Capital and Voting Rights
Aug 7, 2026
Mauna Kea Technologies reported that as of July 31, 2026, its share capital comprised 195,296,487 shares in circulation, corresponding to a gross and net total of 196,383,354 voting rights. The disclosure, made in line with French commercial and m...
Mauna Kea boosts pancreatic cyst diagnosis accuracy with Cellvizio and AI
Jul 28, 2026
Mauna Kea Technologies reported new clinical evidence from two peer-reviewed gastroenterology studies underscoring the value of its Cellvizio needle-based confocal laser endomicroscopy platform in diagnosing pancreatic cystic lesions. The internat...
Mauna Kea Technologies Posts Strong H1 2026 Growth, Bolsters Path to Profitability
Jul 22, 2026
Mauna Kea Technologies reported first-half 2026 revenue of €3.2 million, up 44% at constant currency, driven by clinical adoption of Cellvizio in pancreatic cysts in the United States and rapid international uptake of CellTolerance for food ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.